Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report

Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report

Abstract Venetoclax with high‐dose methotrexate and rituximab seem effective and safe to treat central nervous system involvement of chronic lymphocytic leukemia.

Bibliographic Details
Main Authors: Guillaume Beziat, Martin Gauthier, Caroline Protin, Lucie Oberic, Fleur Lerebours, Jasmine Carlier, Loïc Ysebaert
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Clinical Case Reports
Subjects:
central nervous system involvement
chronic lymphocytic leukemia
venetoclax
Online Access:https://doi.org/10.1002/ccr3.2580
id doaj-048e451d45aa4ca6ae58b9a360d319b3
record_format Article
spelling doaj-048e451d45aa4ca6ae58b9a360d319b32020-11-25T03:48:15ZengWileyClinical Case Reports2050-09042020-02-018226927310.1002/ccr3.2580Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case reportGuillaume Beziat0Martin Gauthier1Caroline Protin2Lucie Oberic3Fleur Lerebours4Jasmine Carlier5Loïc Ysebaert6Department of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse FranceDepartment of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse FranceDepartment of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse FranceDepartment of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse FranceDepartment of Neurology CHU Purpan Toulouse FranceDepartment of Neurology CHU Purpan Toulouse FranceDepartment of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse FranceAbstract Venetoclax with high‐dose methotrexate and rituximab seem effective and safe to treat central nervous system involvement of chronic lymphocytic leukemia.https://doi.org/10.1002/ccr3.2580central nervous system involvementchronic lymphocytic leukemiavenetoclax
collection DOAJ
language English
format Article
sources DOAJ
author Guillaume Beziat
Martin Gauthier
Caroline Protin
Lucie Oberic
Fleur Lerebours
Jasmine Carlier
Loïc Ysebaert
spellingShingle Guillaume Beziat
Martin Gauthier
Caroline Protin
Lucie Oberic
Fleur Lerebours
Jasmine Carlier
Loïc Ysebaert
Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
Clinical Case Reports
central nervous system involvement
chronic lymphocytic leukemia
venetoclax
author_facet Guillaume Beziat
Martin Gauthier
Caroline Protin
Lucie Oberic
Fleur Lerebours
Jasmine Carlier
Loïc Ysebaert
author_sort Guillaume Beziat
title Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
title_short Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
title_full Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
title_fullStr Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
title_full_unstemmed Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
title_sort venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: a case report
publisher Wiley
series Clinical Case Reports
issn 2050-0904
publishDate 2020-02-01
description Abstract Venetoclax with high‐dose methotrexate and rituximab seem effective and safe to treat central nervous system involvement of chronic lymphocytic leukemia.
topic central nervous system involvement
chronic lymphocytic leukemia
venetoclax
url https://doi.org/10.1002/ccr3.2580
work_keys_str_mv AT guillaumebeziat venetoclaxwithhighdosemethotrexateandrituximabseemeffectiveandwelltoleratedinthetreatmentofcentralnervoussysteminvolvementofchroniclymphocyticleukemiaacasereport
AT martingauthier venetoclaxwithhighdosemethotrexateandrituximabseemeffectiveandwelltoleratedinthetreatmentofcentralnervoussysteminvolvementofchroniclymphocyticleukemiaacasereport
AT carolineprotin venetoclaxwithhighdosemethotrexateandrituximabseemeffectiveandwelltoleratedinthetreatmentofcentralnervoussysteminvolvementofchroniclymphocyticleukemiaacasereport
AT lucieoberic venetoclaxwithhighdosemethotrexateandrituximabseemeffectiveandwelltoleratedinthetreatmentofcentralnervoussysteminvolvementofchroniclymphocyticleukemiaacasereport
AT fleurlerebours venetoclaxwithhighdosemethotrexateandrituximabseemeffectiveandwelltoleratedinthetreatmentofcentralnervoussysteminvolvementofchroniclymphocyticleukemiaacasereport
AT jasminecarlier venetoclaxwithhighdosemethotrexateandrituximabseemeffectiveandwelltoleratedinthetreatmentofcentralnervoussysteminvolvementofchroniclymphocyticleukemiaacasereport
AT loicysebaert venetoclaxwithhighdosemethotrexateandrituximabseemeffectiveandwelltoleratedinthetreatmentofcentralnervoussysteminvolvementofchroniclymphocyticleukemiaacasereport
_version_ 1724499404098895872

Similar Items